BACKGROUND: Dual antiplatelet therapy with aspirin and clopidogrel has replaced aspirin and systemic anticoagulation with warfarin as the preferred antithrombotic therapy after percutaneous coronary intervention (PCI) with stent placement. However, a number of patients have indications for all 3 drugs. We sought to determine the frequency and type of hemorrhagic complications in patients who undergo systemic anticoagulation with warfarin while receiving aspirin and clopidogrel after a PCI with stent placement. METHODS: We performed a retrospective analysis of the Mayo Clinic PCI database and identified 66 consecutive patients who were discharged from hospital after PCI between January 2000 and August 2002 (inclusive) receiving a combination of dual antiplatelet therapy (aspirin and clopidogrel) and systemic anticoagulation (warfarin) to determine the incidence of bleeding and other clinical events during the treatment period. RESULTS: Six patients (9.2%; 95% CI, 3.5-19.0) reported a bleeding event; 2 patients required a blood transfusion. No patient died or sustained a myocardial infarction or stent thrombosis. CONCLUSIONS: The risk of bleeding may be increased in patients treated with aspirin, a thienopyridine, and warfarin early after PCI with stent placement.
BACKGROUND: Dual antiplatelet therapy with aspirin and clopidogrel has replaced aspirin and systemic anticoagulation with warfarin as the preferred antithrombotic therapy after percutaneous coronary intervention (PCI) with stent placement. However, a number of patients have indications for all 3 drugs. We sought to determine the frequency and type of hemorrhagic complications in patients who undergo systemic anticoagulation with warfarin while receiving aspirin and clopidogrel after a PCI with stent placement. METHODS: We performed a retrospective analysis of the Mayo Clinic PCI database and identified 66 consecutive patients who were discharged from hospital after PCI between January 2000 and August 2002 (inclusive) receiving a combination of dual antiplatelet therapy (aspirin and clopidogrel) and systemic anticoagulation (warfarin) to determine the incidence of bleeding and other clinical events during the treatment period. RESULTS: Six patients (9.2%; 95% CI, 3.5-19.0) reported a bleeding event; 2 patients required a blood transfusion. No patient died or sustained a myocardial infarction or stent thrombosis. CONCLUSIONS: The risk of bleeding may be increased in patients treated with aspirin, a thienopyridine, and warfarin early after PCI with stent placement.
Authors: Renato D Lopes; Jonathan P Piccini; Elaine M Hylek; Christopher B Granger; John H Alexander Journal: J Thromb Thrombolysis Date: 2008-09-21 Impact factor: 2.300
Authors: Stacey Knight; Raymond O McCubrey; Zhong Yuan; Scott C Woller; Benjamin D Horne; T Jared Bunch; Viet T Le; Roger M Mills; Joseph B Muhlestein Journal: Ther Adv Cardiovasc Dis Date: 2016-02-25
Authors: Craig T January; L Samuel Wann; Joseph S Alpert; Hugh Calkins; Joaquin E Cigarroa; Joseph C Cleveland; Jamie B Conti; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Katherine T Murray; Ralph L Sacco; William G Stevenson; Patrick J Tchou; Cynthia M Tracy; Clyde W Yancy Journal: Circulation Date: 2014-03-28 Impact factor: 29.690
Authors: Salvatore Brugaletta; Victoria Martin-Yuste; Ignacio Ferreira-González; Clarissa Cola; Luis Alvarez-Contreras; Marta De Antonio; Xavier Garcia-Moll; Joan García-Picart; Vicens Martí; Jordi Balcells-Iranzo; Manel Sabaté Journal: World J Cardiol Date: 2011-11-26
Authors: Diana M Rydberg; Lennart Holm; Stefan Mejyr; Desirée Loikas; Karin Schenck-Gustafsson; Mia von Euler; Björn Wettermark; Rickard E Malmström Journal: Eur J Clin Pharmacol Date: 2013-10-06 Impact factor: 2.953
Authors: Kari L Olson; Thomas Delate; Samuel G Johnson; Erika Dawn Wilson; Daniel M Witt Journal: J Thromb Thrombolysis Date: 2010-04 Impact factor: 2.300